(CercleFinance.com) – Biocorp announces the signing of a contract for the sale by its main shareholder BIO JAG, of 1,998,800 shares (i.e. 45.3% of the capital and 62.2% of the voting rights), to a price of 35 euros per share, to Novo Nordisk.
Completion of the acquisition of this block of control as well as the shares held by minority shareholders, representing together 64.4% of the capital and 75.3% of the voting rights, is subject to obtaining the usual regulatory authorizations.
As a result of the contemplated transaction, Novo Nordisk will compulsorily file with the AMF, during the third quarter of 2023, a draft simplified takeover bid, at a price that would value 100% of Biocorp at 154, 4 million euros.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
